glp-1/gip peptide Science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements Targeting GLP-1, GIP & GCG

Q J Med 1972;41:437e56

Subsequent to the approval of exenatide, additional GLP-1 RAs have been FDA-approved, with differences across agents in indication for use (eg, pediatrics), route and/or intervals of administration, pharmacology, efficacy, and tolerability

The activation of cAMP-PKA signaling in gut IELs can inhibit the phosphorylation of Zeta-chain-associated protein kinase-70 (ZAP-70), stopping the signal from TCR, resulting in the inhibition of the immunological response of T cells (Wong et al., 2022

Check your health markers: Regularly test blood sugar, cholesterol, and vitamin levels

Obesity is among the most consequential diagnoses in risk adjustment, HCC capture, and chronic disease management